Mike Lattanzi, MD, discusses key findings from and implications of the PROpel trial in patients with metastatic castration-resistant prostate cancer.
Mike Lattanzi, MD
Advertisement
Articles by Mike Lattanzi, MD
Mike Lattanzi, MD, discusses clinical trials that have evaluated the use of PARP inhibitor–based combination regimens in patients with mCRPC.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Relacorilant Plus Nab-Paclitaxel Meets OS End Point of ROSELLA Trial in PROC
2
Treatment Individualization Is Increasingly Vital With T-DXd Poised to Enter Early-Stage HER2+ Breast Cancer Paradigm
3
FDA Approves Guardant360 as Encorafenib Companion Diagnostic in BRAF V600E-Mutant mCRC
4
INAVO123 Set to Determine Upfront Role of Inavolisib in PIK3CA-Mutant, HR+ Breast Cancer
5